Combination treatment is typically more effective than treatment with methotrexate alone, but some patients may experience adverse events with methotrexate that make monotherapy desirable.
A new study published in Arthritis & Rheumatology found that patients with rheumatoid arthritis (RA) treated with tocilizumab (Actemra, developed by Roche) plus methotrexate who have achieved low disease activity can discontinue methotrexate without significant worsening of disease activity.1 Combination treatment is typically more effective than treatment with methotrexate alone, but some patients may experience adverse events with methotrexate that make monotherapy desirable.
Tocilizumab is an interleukin-6 inhibitor indicated to treat patients with moderate to severe RA who have had an inadequate response to 1 or more disease-modifying anti-rheumatic drugs. Additionally, tocilizumab is also indicated to treat giant cell arteritis in adult patients, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.
Read more about interleukin-6 inhibitors.
This study, COMP-ACT, a randomized, multicenter, double-blind, parallel group trial, compared tocilizumab plus methotrexate with tocilizumab monotherapy in adult patients with RA who had previous inadequate responses to methotrexate. At baseline, all patients began treatment with subcutaneous tocilizumab, either weekly or every 2 weeks, and continued to receive a pre-baseline dose of oral methotrexate.
At 24 weeks, patients who reached disease activity score in a count of 28 joints with erythrocyte sedimentation rate (DAS28-ESR) of 3.2 or lower were then randomized to either discontinue methotrexate and continue tocilizumab as a monotherapy or stay on tocilizumab plus methotrexate until week 52.
Researchers found that patients who received tocilizumab plus methotrexate who had achieved low disease activity were able to discontinue methotrexate without significant worsening of disease activity in the following 16 weeks.
For patients who prefer monotherapy, these results will likely be welcome news. They may also be welcome news for Roche, for whom Actemra has been fairly lucrative, earning the company around $1.9 million last year.
Because the biologic is still covered by patents, there has been relatively little development of tocilizumab biosimilars. However last month, Bio-Thera, a Chinese-based biotechnology company, announced that it has initiated a phase 1 clinical trial for its proposed tocilizumab biosimilar, BAT1806.
Reference
Kremer J, Rigby W, Singer N, et al. Sustained response following discontinuation of methotrexate in patients with rheumatoid arthritis treated with subcutaneous tocilizumab [published online March 25, 2018]. doi.org/10.1002/art.40493.
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
May 18th 2024A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars
May 15th 2024At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.